Tillväxtverket pilot study for hPSC derived cell therapies Innovation catalyst
Varför ska vi samverka mellan intressenter med olika kompetenser, erfarenheter och förutsättningar?
The Novo Nordisk/Karolinska Institutet/St Erik/Vecura model
Integrin a10b1 selected MSC in clinical development for Osteoarthritis and wound healing
Nyligen publicerats av Innovationsmiljön ATMP 2030 “Ökad kunskap och säkrad framtida kompetensförsörjning” arbetsgrupp
Register for ATMP 2030 launch, ATMP world tour and the CAMP + IndiCell hPSC-ATMP tour
Innovationsmiljö 'Sverige ledande inom avancerade terapier 2030'
The innovation milieu 'Sweden a world leader in advanced therapies 2030'
The national strategic project Swelife-ATMP has ended and the final report is now available
Ny rapport om Implementering av avancerade terapier och innovativa läkemedel i svensk hälso- och sjukvård
Closed symposia on the challenges in development of hPSC-ATMP and collaborative potential to drive the field forwards
Karolinska Institutet hosts Doug Melton on ZOOM January 11th 2022
Working towards improving outcomes of lung transplantations with PulmoStem
Matfors to be world leading in industrial ATMP manufacture
Press invitation: ATMP Sweden 2021
Enabling industrial scale production of mRNA and DNA based ATMPs and vaccines
Sweden’s BICO drives better and more accessible healthcare worldwide
Towards more industry engagement
Idogen's immune tolerance platform offers potential solutions to gene and cell therapies.
Robert Langer. Moderna founder, to present at ATMP Sweden 2021
MIT, Moderna and Bill Gates, leading the world in mRNA gene delivery medicines
An important step for patients with metastatic uveal melanoma.
Including launch of our ATMP Introductory course!
ATMP Sweden is about to get a new look
A Swedish precision medicine ATMP
Driving International dialogue in cell and gene therapy
Catch up on the latest including Swedish COVID-19 ATMPs and the ATMP world tour 2021!
Donors, manufacture, pharmacy and clinic....what permits are needed by who and from whom? What quality standards?
Tips for setting up MPA approved GMP manufacture facilities within a small cell therapy company
Catch up on the latest including launch of the commercialisation resources developed by Swelife-ATMP!
Find information and tools to assist in establishing your business model.
Develop your science, transverse skills and competencies to drive the next generation of ATMPs!
Together with KTH/AdBIOPRO and AstraZeneca, will explore scaleable magnetic-based cell separation
Where are we right now with Swedish ATMP manufacture, research and industry?
First foreign Company to join the Swedish ATMP network
Improved preservation of insulin production over 12 months in newly diagnosed adult type-1 diabetes patients
Three severly ill patients are now long term survivors in remission
Catch up on the latest including great results from our CAMP cell therapy project for Malignant Melanoma
Swelife-ATMP SDP4 releases their report on international competitiveness within Swedish gene therapy
48 million SEK partnership to develop pluripotent cell based cell therapy for Dry Macular Degeneration
Swelife-ATMP project SDP3 invitates comments and input on implications.
CellProtect Nordic Pharmaceuticals AB rebrands to XNK Therapeutics AB
Patients and their families are cautioned against using unproven cell based therapies.
Karolinska University Hospital and Karolinska Institutet become first Swedish CCC.
New Danaher operating company created following completion of $21.4B acquisition
Outlines and elaborating EuropaBio’s position and policy recommendations to the European Commission (EC)
CAMP HQ plasmid and pre-GMP projects pave way for Corona vaccine project
The latest on the 2020 conference and more
Interview with network coordinator Lilian Walther Jallow
"To keep up with the potential of this field we need to think and work innovatively, not competitively"
Sjöberg foundation awards 6 million over 3 years to engineering of T cells against Hepatocellular Carcinoma
Please spread this information to those with patients relevant to this trial.
Applications due 31st January, 2020.
Find ATMP relevant events in 2020 and links to sign up!
See our newsletter here and subscribe to receive directly!
Focus on precision medicine and ATMP
Vinnova awards 10 million SEK over two years to secure Sweden's ATMP future
Creates global cell and gene therapy manufacturing services platform
Promising results from Swedish study published in The New England Journal of Medicine
Two great courses covering some ATMP science and the field as a whole
Part 2 of our September 2019 ATMP financing events in Skåne.
Cobra Biologics invests 200 million SEK in Matfors facility
Genetically engineered bacteria to drive wound healing
Part one of our summary of ATMP financing events in Skåne September 2019
A centre for development of the next generation NK cell-based immunotherapies against cancer to be built from Karolinska Institutet.
Register for our finance events and AdBIOPRO bioreactor course
KARO1 is the first GMP hESC line produced at Vecura, there are more to come!
Real examples of taking ATMPs from research to market approval. Who do you need to be partnering with!?
Swedish gene therapy clinical trial for RLBP1 Retinitis Pigmentosa ongoing in Stockholm, Sweden
Sweden drives National and International collaboration to improve quality of life for burns survivors, saved through skin stem cell transplants
The Conference edition of our Newsletter! Read more about the success that was ATMP Sweden 2019!
The era of gene and cell therapy treatments is here!
Advanced therapies for future Healthcare
Good news from of one of our CAMP Projects "Expansion of GMP Compliant Tumor Infiltrating Lymphocytes (TILs) in Xuri bioreactor".
We are pleased to hear that Johan Hyllner has been recruited to AstraZeneca as Head of their Cell and Gene Therapy program.
VOG (tissue area Group) cell represents a National network of University hospitals in Sweden.
It's too cold to go outside, browse our newsletter instead!
Cobra is currently expanding capacity in both Keele, UK and Matfors, Sweden.
We caught up with Johan to see what his plans are post Catapult.
As part of CAMP WP1/WP2 Karolinska Institutet is setting up a pre-GMP core facility.
Welcome to the first CAMP/Swelife-ATMP quarterly ATMP newsletter!